Google
QTTB 株価分析 — Q32 Bio Inc (Healthcare >> Biotechnology)
QTTB に関するよくある質問
QTTBのPER（株価収益率）は？
Q32 Bio Inc（QTTB）は現在PER 7.80倍で取引されています。
QTTBのROE（自己資本利益率）は？
Q32 Bio IncのROEは71.78%です。
QTTBの配当利回りは？
Q32 Bio Incの配当利回りは0.00%です。
QTTBの品質スコア（Quality Score）は？
当社のAIはQTTBの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
QTTBは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
QTTBはどのセクターに属しますか？
Q32 Bio IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
QTTB AI Analysis Summary
Our AI summary for QTTB: Q32 Bio Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 7.80, ROE of 71.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.16
Price
0.99
(6.53%)
Day Change
|
|
|---|
QTTB, ファンダメンタルスコアはok ( ファンダメンタル = 69) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
96
GOOD
|
| Magic Formula Rank by ROE |
96
GOOD
|
| Magic Formula Rank by ROIC |
105
|
| Price | 16.16 |
| PBV / Sector |
9.73 / 44,022.72
|
| Earning Per Share | 1.19 |
| PE / Sector |
7.80 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
47.34 M
GREAT
|
| Average 1W Daily Value |
8.28 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:45 |
| Symbol | QTTB |
| Name | Q32 BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 450.53 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 830 Winter Street, Waltham, MA, United States, 02451
Phone: 781 999 0232
Website: https://www.q32bio.com
Sector: Healthcare >> Biotechnology
Description: Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
